Mesoblast Posts $36M Ryoncil Q4 Sales, $115M Fiscal Revenue
MESO•Mesoblast reported Ryoncil net revenue of $36 million for the quarter ended June 30, 2026, driving full-year net revenue to $115 million. The company highlighted a strong capital position, funding operations through revenue growth and leveraging a new five-year facility to support label extensions and blockbuster initiatives.
1. Strong Q4 and Fiscal Year Revenue
Mesoblast generated $36 million in net revenue from Ryoncil during the quarter ended June 30, 2026, contributing to a first full-year net revenue of $115 million and surpassing its initial projections for the product.
2. Strategic Financial Position
The company emphasized a robust capital position, noting that operational activities are well funded by revenue growth and benefit from a newly operational five-year manufacturing and R&D facility that frees up resources for strategic initiatives.
3. FDA Approval and Market Exclusivity
Ryoncil is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease in patients under 12, granting Mesoblast exclusive U.S. commercialization rights in this indication.
4. Pipeline and Expansion Plans
Mesoblast intends to pursue label extensions of remestemcel-L for adult SR-aGvHD and biologic-resistant inflammatory bowel disease, while advancing rexlemestrocel-L for heart failure and chronic low back pain through partnerships in Japan, Europe and China.
